Zacks Investment Research lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other brokerages also recently weighed in on KURA. BidaskClub upgraded Kura Oncology from a sell rating to a hold rating in a research note on Saturday, September 29th. Cann initiated coverage on Kura Oncology in a research note on Monday, November 5th. They set a buy rating and a $35.00 target price on the stock. Cowen restated a buy rating on shares of Kura Oncology in a research note on Monday, October 22nd. HC Wainwright set a $31.00 target price on Kura Oncology and gave the stock a buy rating in a research note on Thursday, November 1st. Finally, ValuEngine upgraded Kura Oncology from a hold rating to a buy rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $27.29.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.01. As a group, equities research analysts anticipate that Kura Oncology will post -1.73 earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in Kura Oncology by 19.7% during the 3rd quarter. BlackRock Inc. now owns 2,396,137 shares of the company’s stock valued at $41,932,000 after purchasing an additional 393,872 shares during the last quarter. Eagle Asset Management Inc. grew its stake in Kura Oncology by 51.4% during the 3rd quarter. Eagle Asset Management Inc. now owns 2,070,417 shares of the company’s stock valued at $36,232,000 after purchasing an additional 703,282 shares during the last quarter. Victory Capital Management Inc. grew its stake in Kura Oncology by 3.2% during the 3rd quarter. Victory Capital Management Inc. now owns 1,536,310 shares of the company’s stock valued at $26,885,000 after purchasing an additional 47,070 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in Kura Oncology during the 2nd quarter valued at about $16,853,000. Finally, Sio Capital Management LLC grew its stake in Kura Oncology by 27.4% during the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after purchasing an additional 180,193 shares during the last quarter. Institutional investors and hedge funds own 77.28% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: Penny Stocks, Risk and Reward Factors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.